The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 25, 2023

Filed:

Aug. 20, 2019
Applicant:

Arvinas Operations, Inc., New Haven, CT (US);

Inventors:

Andrew P. Crew, Guilford, CT (US);

Hanqing Dong, Madison, CT (US);

Michael Berlin, Flemington, NJ (US);

Steven M. Sparks, Guilford, CT (US);

Assignee:

Arvinas Operations, Inc., New Haven, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/427 (2006.01); A61K 47/54 (2017.01); A61K 31/4035 (2006.01); A61K 31/4245 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/541 (2006.01);
U.S. Cl.
CPC ...
A61K 31/427 (2013.01); A61K 31/4035 (2013.01); A61K 31/4245 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61K 31/541 (2013.01); A61K 47/555 (2017.08);
Abstract

The present disclosure relates to bifunctional compounds, which find utility as modulators of α-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon. Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.


Find Patent Forward Citations

Loading…